— ECOG PS
— Tumor ER/PR and HER2/neu status of metastatic site
— Prior lines of therapy in adjuvant and metastatic breast cancer setting
— Visceral vs nonvisceral metastases
TAKING ALL FACTORS INTO ACCOUNT ENABLES YOU TO ADDRESS THE NEEDS OF YOUR PATIENTS WITH mBC
ECOG PS=Eastern Cooperative Oncology Group performance status;
ER=estrogen receptor; PR=progesterone receptor; HER2/neu=human epidermal growth factor receptor 2.
Studies in patients with mBC have shown that
A range of 51.5%-82.9% of patients with mBC had visceral metastases in 3 retrospective studies (n=263-640) and 1 prospective study (n=486) conducted in various European countries.
These studies analyzed the impact of patient and tumor characteristics on efficacy measures such as OS and do not reflect the efficacy outcomes of the clinical trial of HALAVEN® (eribulin mesylate) Injection vs TPC (13.2 months in the HALAVEN arm vs 10.6 months in the TPC arm).3,6,7
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.3.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed January 11, 2018. 2. Savci-Heijink CD, Halfwerk H, Hooijer GKJ, Horlings HM, Wesseling J, van de Vijer MJ. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150(3):547-557. 3. Bonotto M, Gerratana L, Poletto E, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014;19(6):608-615. 4. Wallwiener M, Hartkopf AD, Baccelli I, et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat. 2013;137:503-510. 5. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;104(8):1742-1750. 6. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000;59(3):271-278. 7. HALAVEN [package insert]. Woodcliff Lake, NJ: Eisai Inc.